Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Calliditas Therapeutics stock
Learn how to easily invest in Calliditas Therapeutics stock.
Calliditas Therapeutics is a biotechnology business based in the US. Calliditas Therapeutics shares (CALT) are listed on the NASDAQ and all prices are listed in US Dollars. Calliditas Therapeutics employs 137 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Calliditas Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CALT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Calliditas Therapeutics stock price (NASDAQ: CALT)Use our graph to track the performance of CALT stocks over time.
Calliditas Therapeutics shares at a glance
|Latest market close||$14.15|
|52-week range||$12.55 - $27.50|
|50-day moving average||$17.82|
|200-day moving average||$18.75|
|Wall St. target price||$61.75|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||N/A|
Buy Calliditas Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Calliditas Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Calliditas Therapeutics price performance over time
|1 week (2022-09-20)||-5.73%|
|1 month (2022-08-26)||-11.62%|
|3 months (2022-06-28)||-20.21%|
|6 months (2022-03-28)||-22.53%|
|1 year (2021-09-28)||-34.85%|
|2 years (2020-09-28)||-41.04%|
|3 years (2019-09-24)||N/A|
|5 years (2017-09-24)||N/A|
Calliditas Therapeutics financials
|Gross profit TTM||$229.3 million|
|Return on assets TTM||-29.11%|
|Return on equity TTM||-72.35%|
|Market capitalisation||$365.1 million|
TTM: trailing 12 months
Calliditas Therapeutics share dividends
We're not expecting Calliditas Therapeutics to pay a dividend over the next 12 months.
Calliditas Therapeutics share price volatility
Over the last 12 months, Calliditas Therapeutics's shares have ranged in value from as little as $12.55 up to $27.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calliditas Therapeutics's is 1.4058. This would suggest that Calliditas Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Calliditas Therapeutics overview
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden. .
Calliditas Therapeutics in the news
Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy
Frequently asked questionsWhat percentage of Calliditas Therapeutics is owned by institutions?
Currently 3.291% of Calliditas Therapeutics shares are held by institutions. How many people work for Calliditas Therapeutics?
Latest data suggests 137 work at Calliditas Therapeutics. When does the fiscal year end for Calliditas Therapeutics?
Calliditas Therapeutics's fiscal year ends in December. Where is Calliditas Therapeutics based?
Calliditas Therapeutics's address is: Kungsbron 1, D5, Stockholm, Sweden, 111 22 What is Calliditas Therapeutics's ISIN number?
Calliditas Therapeutics's international securities identification number is: US13124Q1067
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert